Share information
234.10 €
+1.34 %
06/05/2026 12:23
+1.34 %
Open
High
Low
Volume
232.50 €
234.90 €
231.40 €
26,064
Latest News
03-May-2026
UCB to acquire Candid Therapeutics, building upon its existing immunology pipeline with novel T-cell engagers
01-May-2026
UCB announces acquisition of IMIDomics’ Patient Insight Business, strengthening capabilities in immune-mediated inflammatory diseases (IMIDs)
30-Apr-2026
UCB’s General Meeting of Shareholders 2026
24-Apr-2026
Acquisition of own shares